In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Compumedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:CMP - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	50	0	-1	2	N/A
3/31/2024	50	0	-1	2	N/A
12/31/2023	50	1	-1	2	N/A
9/30/2023	47	-2	-3	1	N/A
6/30/2023	43	-6	-4	0	N/A
3/31/2023	42	-6	-3	1	N/A
12/31/2022	41	-6	-2	2	N/A
9/30/2022	40	-2	-1	2	N/A
6/30/2022	39	1	0	3	N/A
3/31/2022	37	1	0	3	N/A
12/31/2021	34	0	0	2	N/A
9/30/2021	35	0	0	2	N/A
6/30/2021	36	1	0	1	N/A
3/31/2021	35	-2	1	2	N/A
12/31/2020	35	-5	2	4	N/A
9/30/2020	35	-5	1	4	N/A
6/30/2020	35	-6	1	5	N/A
3/31/2020	38	-1	0	5	N/A
12/31/2019	41	3	-1	5	N/A
9/30/2019	41	4	0	5	N/A
6/30/2019	42	4	1	5	N/A
3/31/2019	41	3	1	4	N/A
12/31/2018	40	3	0	3	N/A
9/30/2018	38	3	-1	2	N/A
6/30/2018	37	3	-1	1	N/A
3/31/2018	36	2	N/A	0	N/A
12/31/2017	34	2	N/A	-1	N/A
9/30/2017	34	2	N/A	0	N/A
6/30/2017	34	1	N/A	1	N/A
3/31/2017	35	1	N/A	2	N/A
12/31/2016	36	2	N/A	4	N/A
9/30/2016	37	2	N/A	3	N/A
6/30/2016	38	3	N/A	2	N/A
3/31/2016	36	3	N/A	2	N/A
12/31/2015	35	3	N/A	1	N/A
9/30/2015	34	2	N/A	2	N/A
6/30/2015	33	2	N/A	2	N/A
3/31/2015	33	2	N/A	1	N/A
12/31/2014	32	1	N/A	0	N/A
9/30/2014	31	1	N/A	1	N/A
6/30/2014	31	1	N/A	1	N/A
3/31/2014	30	0	N/A	1	N/A
12/31/2013	28	0	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CMP's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if CMP's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if CMP's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CMP's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if CMP's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CMP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 10:40
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compumedics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ian Martin	New Street Research LLP
Paul Jensz	PAC Partners Securities Pty. Ltd.
Stephen Scott	Taylor Collison Limited

Compumedics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Compumedics Limited Provides Revenue Guidance for the Year 2023

Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023

Compumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023

Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023

Price target lowered to AU$1.00

Compumedics Limited Announces Not to Provide Guidance for the Fiscal Year 2021

Recent updates

Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.

This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks Appropriate

Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)

Compumedics Limited, Annual General Meeting, Oct 31, 2024

Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)

New minor risk - Shareholder dilution

Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% Bounce

New minor risk - Share price stability

Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)

New major risk - Share price stability

We Think Compumedics (ASX:CMP) Has A Fair Chunk Of Debt

Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)

Compumedics Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.008 profit in FY 2022)

Compumedics Limited Provides Revenue Guidance for the Year 2023

Is Compumedics (ASX:CMP) A Risky Investment?

Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023

First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)

Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A Company

Compumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023

No independent directors

Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This Year

Compumedics (ASX:CMP) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)

Compumedics Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)

Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023

Is Compumedics (ASX:CMP) Using Debt Sensibly?

No independent directors

Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022

First half 2022 earnings: EPS and revenues miss analyst expectations

Compumedics (ASX:CMP) May Have Issues Allocating Its Capital

Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)

Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)

Compumedics (ASX:CMP) Will Want To Turn Around Its Return Trends

Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden

Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)

New 90-day low: AU$0.41

These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt Extensively

First half 2021 earnings released: EPS AU$0.007 (vs AU$0.001 in 1H 2020)

How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?